Eli Lilly and Company (NYSE:LLY) PT Raised to $900.00 at JPMorgan Chase & Co.

Eli Lilly and Company (NYSE:LLY – Get Free Report) had its price objective lifted by JPMorgan Chase & Co. from $850.00 to $900.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 22.45% from […]

Related Keywords

Eli Lilly ,Versant Capital Management Inc ,Company Stock Performance ,Company Profile ,Dz Bank ,Pitti Group Wealth Management ,Company Daily ,Moseley Investment Management Inc ,Goldman Sachs Group ,Morgan Stanley ,Jpmorgan Chase Co ,Peaks Wealth Advisors ,Ulland Investment Advisors ,Get Free Report ,Company Stock ,Capital Management Inc ,Group Wealth Management ,Investment Advisors ,Moseley Investment Management ,Investment Management ,Company ,Humalog Mix ,Eli Lilly And Company ,Nyse Lly ,Rally ,Medical ,53245710 ,Boost Price Target ,